K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients  by Barreto, F.C. et al.
see commentary on page 674
K/DOQI-recommended intact PTH levels do not
prevent low-turnover bone disease in hemodialysis
patients
FC Barreto1, DV Barreto1, RMA Moyse´s2, KR Neves2, MEF Canziani1, SA Draibe1, V Jorgetti2 and
AB Carvalho1
1Division of Nephrology, Department of Internal Medicine, Federal University of Sa˜o Paulo, Sa˜o Paulo, Brazil and 2Division of
Nephrology, Department of Internal Medicine, University of Sa˜o Paulo, Sa˜o Paulo, Brazil
The guidelines proposed by the Kidney Disease Outcomes
Quality Initiative (K/DOQI) suggested that intact parathyroid
hormone (iPTH) should be maintained in a target range
between 150 and 300 pg ml1 for patients with stage 5
chronic kidney disease. Our study sought to verify the
effectiveness of that range in preventing bone remodeling
problems in hemodialysis patients. We measured serum
ionized calcium and phosphorus while iPTH was measured by
a second-generation assay. Transiliac bone biopsies were
performed at the onset of the study and after completing
1 year follow-up. The PTH levels decreased within the target
range in about one-fourth of the patients at baseline and at
the end of the study. The bone biopsies of two-thirds of the
patients were classified as showing low turnover and a one-
fourth showed high turnover, the remainder having normal
turnover. In the group achieving the target levels of iPTH
88% had low turnover. Intact PTH levels less than
150 pg ml1 for identifying low turnover and greater than
300 pg ml1 for high turnover presented a positive predictive
value of 83 and 62%, respectively. Our study suggests that
the iPTH target recommended by the K/DOQI guidelines was
associated with a high incidence of low-turnover bone
disease, suggesting that other biochemical markers may be
required to accurately measure bone-remodeling status in
hemodialysis patients.
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Renal osteodystrophy (ROD) is an alteration of bone
morphology that occurs in patients with chronic kidney
disease (CKD).1 ROD comprises a wide spectrum of
manifestation that includes high-turnover states, such as
predominant hyperparathyroid bone disease (PHBD) and
mixed uremic osteodystrophy (MUO), and low-turnover
states, such as osteomalacia and adynamic bone disease
(ABD). Our understanding of this complex disorder has
evolved during the last decades. Nevertheless, its evaluation
continues to be a challenge for the practicing nephrologists.
Bone biopsy is required for the definitive diagnosis of
ROD.1 The invasive nature of the procedure as well as its cost
and overall complexity has withdrawn it from the clinical
practice. Hence, serum markers of bone turnover have been
used to evaluate bone turnover in CKD patients. Measure-
ment of intact parathyroid hormone (iPTH) has long been
considered the principal biochemical marker for diagnosis
and monitoring therapy of ROD.2 In 1986, Sherrard and
co-workers3 suggested that iPTH could be a good predictor
of osteitis fibrosa in patients undergoing maintenance
hemodialysis. Further studies have demonstrated the direct
relationship between iPTH and bone histomorphometric
parameters, mainly bone formation rate.4–7 Consequently,
iPTH has taken the leading position among the non-invasive
tools for assessing ROD. Recently, the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
(NKF K/DOQI) Clinical Practice Guidelines for Bone
Metabolism and Disease in Chronic Kidney Disease have
provided guidance on the use of iPTH to evaluate ROD. A
target range of plasma iPTH for stage 5 CKD patients has
been suggested to be between 150 and 300 pg ml1.8
Although this evidence-based target has been backed on
well-designed studies,4–7 they were performed more than a
decade ago, when the management of ROD was quite
different from now.
This study is part of a randomized controlled trial
comparing the effects of sevelamer with those of calcium
acetate on bone metabolism of chronic hemodialysis patients.
Despite not being the primary purpose of the study, it was
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used to examine the effectiveness of the K/DOQI-proposed
target range of iPTH in preventing bone remodeling
derangements in stage 5 CKD patients.
RESULTS
A total of 101 patients were enrolled in the study. Ninety-
seven patients provided adequate bone samples for
histomorphometric analysis. Table 1 shows the demographic
and biochemical characteristics of the patients at baseline.
Results for the entire population and for each histological
group, namely low-turnover bone disease (LT), high-turn-
over bone disease (HT), and NL (normal histology) are
shown. The mean age of the entire population was 49.5±13.1
years, most of them were white (58%) and men (67%). They
were on hemodialysis for 36.4±24.8 months. An association
between LT and being of white race and a trend toward an
association with older age (P¼ 0.07) and diabetes (P¼ 0.07)
was noticed. There was no difference regarding bone findings
between the group allocated to sevelamer and that allocated
to calcium acetate treatment. LT patients also presented
significantly lower serum iPTH levels, and less time on
hemodialysis. The percentage of patients on 2.5 mequiv. l1
dialyzate calcium concentration was significantly higher in LT
as compared to HT. LT patients have been taking a lower dose
of calcitriol.
The histological diagnoses of the first bone biopsies are
shown in Figure 1. LT was the most frequent histological
finding (n¼ 58, 60%; Figure 1a). HT was observed in 36
(37%) patients. The majority of the LT was comprised of
ABD (95%), whereas MUO and PHBD comprised 67 and
33% of the HT group, respectively (data not shown on the
figure). Three patients had normal bone histology. Figure 1b
shows the distribution of these histological findings accord-
ing to the K/DOQI range of iPTH. The most prevalent bone
disorders observed below the lower and above the upper limit
of the iPTH range (150–300 pg ml1) were LT (n¼ 29, 83%)
and HT (n¼ 25, 62.5%), respectively. LT was the most
common finding (n¼ 14, 64%) in the ideal range of iPTH.
Sixty-four patients (aged 47.5±12.7 years, 66% men,
62.5% white) concluded the follow-up. The causes of
dropout were kidney transplantation (n¼ 12), death
(n¼ 9), referral for peritoneal dialysis (n¼ 5), refusal for
second bone biopsy (n¼ 5), and parathyroidectomy (n¼ 2).
These patients did not differ from the ones who completed
the study regarding age (51.6±13.5 vs 47.5±12.7 years),
time on dialysis (34.4±24.6 vs 37.5±25.1 months), serum
phosphorus (5.9±1.2 vs 5.8±1.0 mg per 100 ml),
serum ionized calcium (1.28±0.09 vs 1.28±0.07 mmol l1),
serum iPTH (361.6±337.9 vs 420.4±307.5 pg ml1), and the
histological type of bone lesion.
Figure 2 shows the bone histological findings from first
bone biopsy and how they changed from one category to
another after 1 year. Bone histology did not change in
approximately 60% of the patients with LT (23/37) and HT
(15/26). No patient turned to normal bone histology. The
second bone biopsy could not be performed in 21 and in 10
patients with LT and HT, respectively. The unique patient
with normal bone histology who ended the follow-up
remained in this category. Concerning ROD management
during the study, there was no difference in calcitriol dose,
using 2.5 mequiv. l1 dialysate calcium concentration, type of
phosphate binder, and having been on deferoxamine
treatment, between patients who changed and did not change
their bone histological lesion to another category.
Figure 3 depicts the results of the second bone biopsy after
1-year follow-up. LT was still the most prevalent bone
disorder (n¼ 34, 53%), followed by HT (n¼ 29, 45.5%;
Figure 3a). LT group was comprised mainly of ABD (97%),
whereas PHBD and MUO comprised 62 and 38%, respec-
tively, of the HT group (data not shown on the figure). One
Table 1 | Demographic and biochemical characteristics for the entire population and for each histological group at baseline
Entire population (n=97) LT (n=58) HT (n=36) NL (n=3)
Age (years) 49.5±13.1 50±13.6 45.4±12.2 54.3±4.0
Gender (% male) 65 69 61 33.3
Race (% white) 58 67* 42 66.6
Time on hemodialysis (months) 36.4±24.8 30.1±20.8* 48.2±26.9 36.7±28.9
Diabetes mellitus (%) 16.5 21 8 0
Dialyzate [Ca2+]=2.5 mequiv. l1 (%) 41 52* 25 33.3
Calcitrol dosage (mg day1)a 0.04±0.15 0.01±0.05* 0.09±0.23 0
Phosphate binder (%)b
Calcium acetate 48 50 41.7 66.7
Sevelamer 52 50 58.3 33.3
Serum ionized calcium (mmol l1) 1.28±0.1 1.28±0.1 1.26±0.07 1.36±0.24
Serum phosphorus (mg per 100 ml) 5.4±1.5 5.4±1.6 5.4±1.2 4.9±2.9
Serum iPTH (pg ml1) 391.6±389.9 266.4±316.2* 613.8±414.6 145±72.8
Al.S/BS425% (%) 41 46.5 36 0
Al.S/BS, aluminum bone surface; HT, high-turnover bone disease; iPTH, intact parathyroid hormone; LT, low-turnover bone disease; NL, normal histology.
*Po0.05 vs HT.
aMean dose of calcitriol at baseline.
bRefers to the percentage of patients allocated to each group of phosphate binder at the beginning of the study.
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patient had normal bone histology. Similar to the results of
the first bone biopsy, the most prevalent bone disorders
observed below the lower and above the upper limit of the
iPTH range were LT (n¼ 10, 73%) and HT (n¼ 25, 71%),
respectively. Once again, LT (n¼ 14, 87%) was the most
common finding within the recommended range of iPTH
(Figure 3b). The first bone biopsy from these 16 patients
whose serum iPTH remained in the K/DOQI target range
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Figure 1 | Distribution of renal osteodystrophy pattern of the first bone biopsy. (a) Whole population; (b) according to the K/DOQI PTH ranges.
HT, high-turnover bone disease; LT, low-turnover bone disease; NL, normal histology.
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Figure 3 | Distribution of renal osteodystrophy pattern of the second bone biopsy. (a) Whole population; (b) according to the K/DOQI PTH
ranges. HT, high-turnover bone disease; LT, low-turnover bone disease; NL, normal histology. *The mean level of iPTH during the follow-up was
used to classify patients into the K/DOQI PTH ranges.
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during the 12 months of observation had unveiled the
following histological distribution: 11 LT, 4 HT, and 1 NL.
Only one patient from LT group changed to HT. All patients
from HT changed their bone histology to LT. The patient
with normal bone histology remained within the same
category.
Table 2 shows the demographic and biochemical
characteristics of the patients within the ideal range of iPTH,
at the baseline and after 1-year follow-up. There was no
difference between LT and HTþNL groups regarding
demographic and biochemical parameters.
Table 3 shows the demographic and biochemical
characteristics of the patients with serum iPTH values above
the upper limit of its target range (4300 pg ml1) at the
baseline. Compared to HT, LT patients presented less time on
hemodialysis, higher phosphorus levels, and have been taking
a lower dose of calcitriol. There was no difference regarding
age, gender, presence of diabetes, percentage of patients on
2.5 mequiv. l1 dialyzate calcium concentration, serum
ionized calcium, iPTH levels, and the percentage of patients
with aluminum intoxication between groups. A borderline
association (P¼ 0.07) between LT and white race was
observed.
Table 4 shows the type of bone disease predicted from the
iPTH level. Intact PTH level below 150 pg ml1 presented a
50% sensitivity, 85% specificity, and 83% positive predictive
value for the diagnosis of LT. In contrast, iPTH level greater
than 300 pg ml1 presented a 69% sensitivity, 75% specificity,
and 62% positive predictive value for the diagnosis of HT.
The positive predictive value of the ideal range of iPTH for
the identification of normal bone histology could not be
performed in this study owing to the low number of patients
with this histological pattern.
DISCUSSION
This study provides a current evaluation of the effectiveness
of the target range of iPTH (150–300 pg ml1), as
recommended by the NKF K/DOQI guidelines, in preventing
Table 2 | Demographic and biochemical characteristics of the patients with iPTH target range (150–300 pg ml1) at baseline and
at the end of the study
Baseline (1st bone biopsy) Ending (2nd bone biopsy)
LT (n=14) HT+NL (n=8) LT (n=14) HT+NL (n=2)
Age (years) 53±14.2 46.7±9.2 48±9.6 51±1.4
Gender (% male) 71 62 57 50
Race (% white) 78 37 57 50
Time on hemodialysis (months) 28.1±22.4 31.5±24 43.2±16.7 44.5±20.5
Diabetes mellitus (%) 28.5 50 21.4 0
Dialyzate [Ca2+]=2.5 mequiv. l1 (%) 57 50 64 50
Calcitriol dosage (mg day1)a 0.01±0.02 0.5±1.0 0.01±0.03 0
Phosphate binder (%)
Calcium acetate 36b 50b 21.4 50
Sevelamer 64b 50b 78.6 50
Serum ionized calcium (mmol l1) 1.27±0.11 1.27±0.1 1.23±0.07 1.3±0.05
Serum phosphorus (mg per 100 ml) 5.3±1.1 5.6±1.4 5.3±1.5 6.6±0.4
Serum iPTH (pg ml1) 210±38 212.2±38.3 224.±44.1 194.5±46.2
Al.S/BS425% (%) 57 37.5 50 50
Al.S/BS, aluminum bone surface; HT, high-turnover bone disease; iPTH, intact parathyroid hormone; LT, low-turnover bone disease; NL, normal.
aMean dose of calcitriol at baseline or during the follow-up.
bRefers to the percentage of patients allocated to each group of phosphate binder at the beginning of the study.
Table 3 | Demographic and biochemical characteristics of the
patients with iPTH higher than 300 pg ml1 at baseline
Baseline (1st bone biopsy)
LT (n=15) HT (n=25)
Age (years) 49.7±16.1 43.4±12.7
Gender (% male) 80 64
Race (% white) 73 44
Time on hemodialysis (months) 38±22* 53.2±28.7
Diabetes mellitus (%) 20 4
Dialyzate [Ca2+]=2.5 mequiv. l1 (%) 33 12
Calcitriol dosage (mg day1)a 0.06±0.1* 0.26±0.25
Serum ionized calcium (mmol l1) 1.24±0.09 1.26±0.07
Serum phosphorus (mg per 100 ml) 6.9±1.9 6.0±1.5
Serum iPTH (pg ml1) 694.2±352.7 803.9±355.3
Al.S/BS425% (%) 60 32
Al.S/BS, aluminum bone surface; HT, high-turnover bone disease; iPTH, intact
parathyroid hormone; LT, low-turnover bone disease.
*Po0.05.
aMean dose of calcitriol at baseline.
Table 4 | Prediction of bone disease based on K/DOQI iPTH
cut-off
Sensitivity Specificity
Positive
predictive value
LT (ABD and OM) cut-off
o150 pg ml1
0.50 0.85 0.83
HT (PHBD and MUO)
cut-off 4300 pg ml1
0.69 0.75 0.62
ABD, adynamic bone disease; HT, high-turnover bone disease; iPTH, intact
parathyroid hormone; LT, low-turnover bone disease; MUO, mixed uremic
osteodystrophy; OM, osteomalacia; PHBD, predominant hyperparathyroid bone
disease.
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abnormalities of bone remodeling in maintenance hemodia-
lysis patients. Furthermore, we analyzed the predictive value
of the iPTH below the lower and above the upper limit of its
target range to identify, respectively, LT and HT in this
population.
Only 2 out of 22 patients with iPTH levels between 150
and 300 pg ml1 presented normal bone histology at baseline.
LT was the most prevalent histological finding in those
patients. Indeed, HT and LT were the most frequent bone
disorder in patients with iPTH levels above 300 pg ml1 and
below 150 pg ml1, respectively. Thereafter, patients were
followed up monthly during 1 year. They were treated to
achieve the goals of the bone metabolism parameters
proposed by the NKF K/DOQI guidelines.8 Strikingly, at
the time point of the second biopsy, LT remained the most
prevalent bone biopsy finding in those patients who had been
able to achieve the iPTH target range as defined by the
K/DOQI guidelines. Souberbielle et al.9 have shown that
Immulite 2000 intact PTH assay exhibits a positive median
bias of 37.8% compared with the Allegro assay, which means
that the iPTH target range would be 212–410 pg ml1 for the
Immulite assay. Even if this bias was taken into account,
the prevalence of LT within this adjusted range would be
similar as compared to that evaluated by Immulite assay
(data not shown).
Although we could observe an association between
traditional factors,10–12 such as aging, diabetes, white race,
less time on hemodialysis and lower PTH levels, and LT in the
entire population, a similar finding could not be observed in
patients with iPTH levels between 150 and 300 pg ml1. This
lack of association may be attributed to the low number of
patients presenting that condition. These results suggest that
K/DOQI target range of iPTH is not necessarily a safe harbor
to bone. Furthermore, even for iPTH 4300 pg ml1, LT was
observed in one-third of the patients. Of note, both LT and
HT patients did not differ in any aspect, but in time on
hemodialysis and dose of calcitriol.
Our data are in contrast with previous studies that have
indicated that optimal iPTH range in dialysis patients
appeared to be 2–4 times the upper limit of its normal
levels.8,13 However, one should consider that most of these
studies were conducted in the early 1990s and many
paradigms have been changed since this period. The use of
aluminum hydroxide in dialysis patients was abandoned.
Vitamin D and calcium-based phosphate binders are now
prescribed with more caution due to their harmful extra
skeletal effects. Treatment goals for ROD management are
stricter. Additionally, new drugs, such as sevelamer, have been
used for the treatment of mineral metabolism derangement.
Although the impact of these advances on bone is not
completely known, they have certainly modified the bone
response to the uremic environment.
The lower cut-off level of the iPTH range provided a
positive predictive value of 83% for the diagnosis of LT. Only
a limited number of patients with HT had iPTH
o150 pg ml1. Conversely, a high proportion of patients
with iPTH 4300 pg ml1 presented LT, based on bone
biopsy. This explains the low (69%) positive predictive value
of the upper cut-off level of the iPTH range for the diagnosis
of HT. Recently, Gal-Moscovici and Popovtzer14 have also
observed the occurrence of LT in patients with high PTH
levels. Different from their study, this study provided
information on the prevalence of ROD pattern according to
the K/DOQI PTH target range. In addition, the prospective
design allowed us to notice that normalization of bone
turnover is difficult to be achieved even in patients who meet
the PTH target range during 1-year follow-up. Other reports
have elegantly raised concerns about the reliability of iPTH
measurement as an indicator of bone turnover in CKD
patients.9,15 Intact PTH assays measure both full-length 1-84
PTH and N-terminal truncated 7-84 PTH fragment.16 These
molecules exhibit distinct actions on bone. It has been
proposed that 7-84 PTH fragment may play a role in skeletal
resistance to PTH observed in stage 5 CKD.17 Indeed, the
assay used for measuring iPTH in this study, that is Immulite,
presents—according to the study conducted by Souberbielle
et al.9—a ratio of recovery of those both compounds o1,
which indicates that the assay crossreacts with 7-84 PTH
fragment less than with 1-84 PTH. Although more specific
PTH assays (1-84 PTH) are currently available,18 there is still
controversy about the clinical advantage of those assays over
the traditional one.19
The applicability of other biochemical markers of bone
turnover in CKD patients, such as bone-specific alkaline
phosphatase, osteocalcin, and collagen breakdown products,
has been investigated.20–22 Their routine use in daily clinical
practice has not been established yet.2,23 Meanwhile, PTH
measurement remains as the main surrogate indicator of
bone turnover in CKD patients. Further, despite its
disadvantages, bone biopsy followed by histomorphometric
analysis is undoubtedly the most conclusive method to
diagnose ROD.
The presence of aluminum intoxication could be a
limitation in this study. Despite not using aluminum-based
phosphate binder and strictly controlling water quality in the
dialysis centers involved in this study, aluminum intoxication
(Al.S/BS425%) was present in 41% of the entire population.
However, one should notice that the amount of aluminum
bone surface was not that high (Al.S/BS¼ 24.3±28.6%).
Other aluminum exposure source that may be important in
patients with CKD, such as aluminum kitchen utensils,24
were not investigated in this study. Other limitation was the
method used for diagnosing aluminum overload. It was
assessed only by bone histomorphometry, and not by a
deferoxamine test, which would be the ideal approach to
exclude aluminum overload.25 It has been reported that the
effect of aluminum on bone would depend on the pattern
and amount of aluminum exposure. Thus, heavy aluminum
loads could lead to a mineralization defect and, consequently,
osteomalacia. In contrast, a long-term low-level aluminum
exposure, combined with other factors that reduce bone
turnover, such as calcium-based phosphate binders, may
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affect bone metabolism inducing a pattern of bone damage
characterized by low bone turnover.26 However, Ferreira et al.
found a similar distribution of bone biopsy findings across
their hemodialysis patients for circulating iPTH values in the
low, normal, or high range, as defined by the K/DOQI
guidelines, in the absence of evidence for aluminum
intoxication (Ferreira et al. Effects of sevelamer and calcium
carbonate on bone mineralization and turnover in chronic
maintenance hemodialysis patients. XLIII ERA-EDTA Con-
gress, Abstract). It should be reinforced that no correlation
was found between aluminum intoxication and the presence
of LT in the studied population. Finally, the low number of
patients in the iPTH target range, especially at the end of the
study, precluded more powerful results. This was a
consequence of the longitudinal design of the study and we
obviously could not control the number of patients
distributed in each PTH range after the follow-up.
In summary, to the best of our knowledge, this is the only
prospective study that investigates bone histology in stage 5
CKD patients with iPTH levels within the target range
recommended by the NKF K/DOQI guidelines. LT was quite
frequent in the recommended iPTH range. Thus, the
so-called ideal range of iPTH does not seem to guarantee a
healthy bone. Additionally, one might conclude that the
upper cut-off of iPTH (300 pg ml1) should be revised. The
poor predictive value of PTH for bone turnover makes it
impossible to guess what the turnover would be in an
individual patient even though statistically there may be
correlation between PTH and bone turnover in the popula-
tion at large. It is worthy mentioning that nephrologists
should be aware that oversuppressing PTH by overuse of
active vitamin D analogs is potentially harmful and
aggravates hyperphosphatemia, hypercalcemia, and, ulti-
mately, vascular calcification. These findings clearly show
the limitations of the current recommendations based on
iPTH levels for the management of ROD in maintenance
hemodialysis patients. Our results underline the importance
of more studies investigating this intricate issue of ROD.
MATERIALS AND METHODS
Study design and patients
This prospective 1-year follow-up study was originally designed as a
randomized controlled trial to compare the effects of two types of
phosphate binders, calcium acetate (PhosLo) and sevelamer
(Renagel), on mineral metabolism, bone turnover, and progression
of coronary calcification in patients undergoing hemodialysis.27
Most importantly, all patients were older than 18 years, on
hemodialysis for at least 3 months, had intact PTH levels below
1000 pg ml1, and should present hyperphosphatemia (serum
phosphorus 45.5 mg per 100 ml) after a 2-week phosphate binder
washout period. None of them had been previously submitted to
parathyroidectomy. Indeed, besides calcium-based phosphate binder
and calcitriol, none of them were using drugs that could interfere in
bone metabolism, such as calcimimetics, corticosteroids, bispho-
sphonates, or hormonal replacement therapy. After the 2-week
washout period, patients were randomized to receive either calcium
acetate or sevelamer and were followed up for 1 year. Patients
were submitted to a bone biopsy at baseline and at the end
of the study. Ionized calcium and phosphorus were measured
monthly and iPTH was measured every 2 months. Investigators
were encouraged to adjust the dose of phosphate binder agent
and calcitriol as well as the dialysate calcium concentration to
achieve the targets proposed by the NKF K/DOQI Clinical
Practice Guidelines for Bone Metabolism and Disease in
Chronic Kidney Disease.8 The target range for ionized calcium
was that of the reference values of the method. Aluminum
intoxication was treated with deferoxamine 5 mg per kg per week,
IV, infused after the end of the first hemodialysis session of the week,
during 6 months.
This study was conducted in four different dialysis centers, all of
them located in the city of Sa˜o Paulo, Brazil. All patients provided
written informed consent. Local ethics committees approved the
study protocol.
Biochemical parameters
Blood samples for the determination of biochemical parameters
were obtained after an overnight fast and before the first
weekly hemodialysis session. Serum ionized calcium (reference
range: 1.11–1.40 mmol l1) and serum phosphorus (reference range:
2.3–4.5 mg per 100 ml) were determined by automated methods.
Serum iPTH was measured by chemiluminescence assay (Immulite,
DPC, Los Angeles, CA, USA; reference range: 10–65 pg ml1).
During the follow-up, the mean serum level of iPTH was used to
classify the patients into the K/DOQI PTH ranges at the end of the
study.
Bone biopsy
Each patient was submitted to two transiliac bone biopsies, one at
the entry and the other at the end of the study, using a standard
technique described previously.28 Bone specimens were obtained
from alternate sides to avoid interference of repair processes at the
site of the previous biopsy. Transiliac bone specimens were obtained
with a 7-mm Bordier trephine after a course of double-labeling
tetracycline (20 mg kg1 day1) for 3 days, separated by an interval
of 10 days. The biopsies were performed 3–5 days after the last dose
of tetracycline and no longer than 1 month after the blood sampling.
After standard processing for histological studies,29 undecalcified
sections of trabecular bone were stained by toluidine blue (pH 6.4)
and acid solochrome azurine for aluminum.30 Unstained sections
were used for tetracycline fluorescence analysis.
Bone histomorphometric analysis was conducted in a double-
blind protocol, using the semiautomatic method provided by
Osteomeasure software (Osteometrics Inc., Atlanta, GA, USA). All
the histomorphometric parameters used were those suggested by the
American Society of Bone and Mineral Research Histomorphometry
Nomenclature Committee.31 The reference ranges used for static
parameters were obtained from local controls, whereas the dynamic
parameters followed those described elsewhere.32
ROD was classified into one of the classical types according to
the following criteria: (1) PHBD, defined as bone formation rate
(BFR/BS; reference range: 0.13±0.07mm3mm2 day1), as well as
either osteoblast surface (Ob.S/BS; reference range: 2.13±3.8%) or
osteoclast surface (Oc.S/BS; reference range: 0.07±0.22%), more
than 1 s.d. above the normal range, osteoid volume (OV/BV;
reference range: 3.2±3.0%) within or above the normal range and
marrow fibrosis 40.5%; (2) ABD, defined as BFR/BS and OV/BV
more than 1 s.d. below the normal range and marrow fibrosis
o0.5%; (3) osteomalacia, defined as BFR/BS more than 1 s.d. below
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the normal range and OV/BV more than 1 s.d. above the normal
range; and (4) MUO, defined as BFR/BS, OV/BV, and mineralization
lag time (reference range: 21.3±2.3 days) more than 1 s.d. above the
normal range and marrow fibrosis 40.5%. Thereafter, these types
were grouped into one of the two major patterns: HT (PHBD and
MUO) or LT (osteomalacia and ABD). Aluminum intoxication was
defined when aluminum bone surface (Al.S/BS) was greater than
25%.
Statistical analysis
Results are expressed as mean±s.d. or percentages. Unpaired t-test
was performed to compare continuous variables, and w2-test or
Fisher’s exact test for binary variables. The predictive value of the
iPTH range for the diagnosis of the bone histological lesion was
expressed in terms of sensitivity, specificity, and positive predictive
value. Po0.05 was considered statistically significant. All statistical
analyses were performed using SPSS 13.0 for Windows software.
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